TG Therapeutics
Price & Volume
Stats
See moreOpen | $41.95 |
Previous Close | $42.03 |
Day Range | $41.68-$43.89 |
52W Range | $14.87-$43.32 |
Market Cap | $6.6B |
Shares Short | 23M |
Financials
See moreRevenue (12 Mos) | $329M |
Revenue Growth (YoY) | 146% |
Gross Profit (12 Mos) | $290.5M |
Diluted EPS | $0.15 |
News
See moreYahoo Finance • 19 days ago
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting
Yahoo Finance • 22 days ago
TG Therapeutics Announces Two Publications Highlighting BRIUMVI in Medical Journals
Yahoo Finance • 2 months ago
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting
Yahoo Finance • 2 months ago
TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2024 Financial Results and Business Update
About
CEO | Mr. Michael S. Weiss Esq. |
CFO | Mr. Sean A. Power CPA |
Address | 3020 Carrington Mill Blvd., Morrisville, NC, United States, 27560 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 338 |
